The size of the Leukemia Therapeutics market in the Middle-East and Africa has been estimated at USD 0.59 Billion in 2021 and is projected to reach USD 0.92 Billion by 2026, at a CAGR of 9.23% during the forecast period from 2021 to 2026.
Leukemia is a type of cancer where abnormal white blood cells crowd the bone marrow and other organs such as the liver, spleen, and kidneys through blood and prevent its normal functions. It is commonly caused due to the high exposure to radiation, an unhealthy lifestyle, genetic factors, and environmental conditions. It is common in adults and is observed to progress with aging.
The factor that is driving the market for Leukemia Therapeutics in Middle-east and Africa is the simultaneous increase in increasing awareness about cancer treatments and drugs, along with increasing occurrence. Also, due to the increasing aging population, the market is driven, as the disease is common with aging.
But the market is feared to decline due to the high costs of treatment and drugs.
This research report on the MEA Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories
By Disease Condition:
By Diagnosis:
By Treatments:
By Drugs:
By Country:
By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.
Factors such as the rising prevalence of Leukemia, growing awareness of cancer screening programs, and raising awareness for healthcare among the population in developing nations of the region are making the companies penetrate into this market.
The leading companies leading in the MEA Leukemia Therapeutics market profiled in the report are F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease Condition
5.1.1 Chronic Lymphatic Leukemia
5.1.2 Acute Lymphatic Leukemia
5.1.3 Chronic Myeloid Leukemia
5.1.4 Acute Myeloid Leukemia
5.2 By Diagnosis
5.2.1 CT scan
5.2.2 Biopsy
5.2.3 MRI
5.3 By Treatments
5.3.1 Chemotherapy
5.3.2 Radiation therapy
5.3.3 Immunotherapy
5.3.4 Surgery
5.3.5 Targeted Therapy
5.3.6 Bone marrow transplant
5.3.7 Stem Cell Therapy
5.4 By Drugs
5.4.1 Gleevec
5.4.2 Sapacitabine
5.4.3 GA101
5.4.4 Vasaroxine
5.4.5 Tosedosat
6. Geographical Analysis
6.1 Introduction
6.2 Middle-East
6.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 F. Hoffmann-La Roche Ltd
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 GlaxoSmithKline Pharmaceuticals Limited
9.3 Novartis International AG
9.4 Bristol-Myers Squibb
9.5 Eisai Co. Ltd
9.6 Biogen Idec
9.7 ERYtech Pharma
9.8 Celgene Corporation
9.9 Genmab A/S
9.10 Cephalon Inc.
9.11 Clavis Pharma
9.12 Pfizer Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
